Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Tracking Triple-negative Breast Cancer Evolution Through Therapy (TRACERX-TNBC)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03077776
Recruitment Status : Recruiting
First Posted : March 13, 2017
Last Update Posted : October 16, 2019
Sponsor:
Collaborator:
National Cancer Institute, France
Information provided by (Responsible Party):
UNICANCER

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
A prospective multicentre study which aims to examine the relationship between intratumour heterogeneity (ITH) and pathological response to neoadjuvant chemotherapy in patients with histological confirmation of triple-negative breast cancer (TNBC) who are eligible for neoadjuvant chemotherapy.

Condition or disease Intervention/treatment Phase
Triple-Negative Breast Neoplasm Procedure: Biopsy Procedure: Biopsy (optional) Procedure: Biopsy (metastatic) Not Applicable

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 250 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Diagnostic
Official Title: Tracking Triple-negative Breast Cancer Evolution Through Therapy
Actual Study Start Date : April 14, 2017
Estimated Primary Completion Date : January 2025
Estimated Study Completion Date : July 2025

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Breast Cancer

Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: All included patients

Patients will undergo a biopsy and provide a blood sample prior to initiating standard neoadjuvant chemotherapy. Additional tissue samples will be collected at the following time points:

  1. (optional) biopsy of primary tumour after 4 cycles of neoadjuvant chemotherapy
  2. At the time of surgery (samples of the primary tumour and lymph nodes which are surplus to diagnostic requirements).
  3. Biopsy of a metastatic site in the event of disease recurrence.

Blood samples will be obtained during neoadjuvant chemotherapy, prior to surgery and at 6-month intervals for up to 5 years post-surgery. In the event of recurrent disease, blood samples will be collected i) at the time of recurrence, ii) at the first CT scan on treatment and iii) at each subsequent relapse for up to 5 years post-surgery.

 Procedure: Biopsy
Biopsy of primary tumour to be performed prior to initiation of neoadjuvant chemotherapy

Procedure: Biopsy (optional)
[Optional] biopsy of primary tumour to be performed after 4 weeks of neoadjuvant chemotherapy

Procedure: Biopsy (metastatic)
Biopsy of metastatic site to be performed at the time of relapse


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Rate of pathological complete response (pCR) [ Time Frame: pCR will be defined at the time of surgery on the tumor specimen ]
    pCR is defined as the absence of residual invasive cancer on hematoxylin and eosin evaluation of the complete resected breast specimen and all sampled ipsilateral lymph nodes (i.e., ypT0/Tis ypN0 in the current American Joint Committee on Cancer [AJCC] staging system)


Secondary Outcome Measures :
  1. Invasive disease-free survival [ Time Frame: from surgery until 5 years post-surgery ]
    the time from neoadjuvant treatment initiation until the date of the first occurrence of one of the following events: invasive ipsilateral breast tumour recurrence (same breast), local /regional invasive recurrence, invasive contra lateral breast cancer, appearance of metastasis, second primary invasive cancer (non-breast cancer), ipsilateral ductal carcinoma in situ, contralateral ductal carcinoma in situ, death attributable to any cause.

  2. Overall survival [ Time Frame: from surgery until 5 years post-surgery ]
    the time from neoadjuvant treatment until death due to any cause


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Age 18-years or older
  2. Patients with histological confirmation of invasive breast cancer with known receptor status suitable for neoadjuvant chemotherapy as assessed by the local investigator
  3. Estrogen receptor (ER)- and progesterone receptor (PR)-negative as defined by ≤1% of positive staining on immunohistochemistry
  4. Human epidermal growth factor receptor 2 (HER2)- negative as defined by American Society of Clinical Oncology / College of American Pathologists guidelines
  5. T1c-4 tumours (including inflammatory cancers), with any nodal status non candidate for conservative surgery upfront. Bilateral or multifocal cancer is permitted provided that all sites are HER2-negative and at least one site is ER- and PR-negative.
  6. Provision of signed and dated, written informed consent prior to any study specific procedures, sampling and analyses
  7. Patient with social insurance coverage

Exclusion Criteria:

  1. Confirmed metastatic disease at initial presentation
  2. Any contraindication to the biopsy procedure
  3. Previous or current malignancies of other origin within the last 5 years, with the exception of in situ carcinoma of the cervix, and adequately treated basal cell or squamous cell carcinoma of the skin
  4. Any condition which in the Investigator's opinion makes it undesirable for the subject to participate in the trial or which would jeopardize compliance with the protocol
  5. Individuals deprived of liberty or placed under the authority of a tutor
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03077776


Contacts
Layout table for location contacts
Contact: Marta JIMENEZ +33 (0)1 44 23 55 58 m-jimenez@unicancer.fr

Locations
Layout table for location information
France
Centre Jean Perrin Recruiting
Clermont-Ferrand, France
Contact: Marie-ANger Mouret-Reynier         
Centre George François Leclerc Recruiting
Dijon, France
Contact: Isabelle Desmoulin         
Centre Leon Bérard Recruiting
Lyon, France
Contact: Olivier TREDAN, MD         
Principal Investigator: Olivier TREDAN, MD         
Institut Paoli Calmettes Recruiting
Marseille, France
Contact: Anthony GONCALVES, MD         
Principal Investigator: Anthony GONCALVES, MD         
Institut de Cancerologie de l'Ouest Not yet recruiting
Nantes, France
Contact: Jean-Sébastien FRENEL, MD         
Principal Investigator: Jean-Sébastien FRENEL, MD         
Centre Eugène Marquis Recruiting
Rennes, France
Contact: Thibault DE LA MOTTE ROUGE, MD         
Principal Investigator: Thibault DE LA MOTTE ROUGE, MD         
Centre Paul Strauss Recruiting
Strasbourg, France
Contact: Thierry Petit, MD         
Principal Investigator: Thierry Petit, MD         
Hopitaux universitaire de strasbourg - Hopital civil Recruiting
Strasbourg, France
Contact: Phillipe Barthelemy         
Institut de Cancérologie de Lorraine Recruiting
Vandœuvre-lès-Nancy, France
Contact: Anne Kieffer         
Gustave Roussy Recruiting
Villejuif, France
Contact: Monica Arnedos, MD       monica.arnedos@gustaveroussy.fr   
Principal Investigator: Monica Arnedos, MD         
Sponsors and Collaborators
UNICANCER
National Cancer Institute, France
Investigators
Layout table for investigator information
Principal Investigator: Monica ARNEDOS, MD Gustave Roussy Cancer Campus
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Additional Information:
UNICANCER official website  This link exits the ClinicalTrials.gov site

Layout table for additonal information
Responsible Party: UNICANCER
ClinicalTrials.gov Identifier: NCT03077776     History of Changes
Other Study ID Numbers: UC-0105/1614
ID RCB: 2016-A01177-44 ( Other Identifier: ANSM )
First Posted: March 13, 2017    Key Record Dates
Last Update Posted: October 16, 2019
Last Verified: October 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Triple Negative Breast Neoplasms
Breast Neoplasms
Neoplasms by Site
 Neoplasms
Breast Diseases
Skin Diseases